Oral acyclovir prophylaxis of varicella after intimate contact

Tzou Yien Lin, Yhu Chering Huang, Hsiao Chen Ning, Chuen Hsueh

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Objectives. Whether oral acyclovir (ACV) given in late incubation can prevent clinical varicella or not. Materials and methods. Twenty-seven healthy infants and children susceptible to varicella received oral ACV (40 mg/kg daily in four divided doses) for 5 days, starting 9 or 11 days after exposure from the index case in the family (2 in the classroom). The clinical features were compared with 13 control children who did not receive ACV. Enzyme-linked immunoassay was used to detect varicella-zoster virus (VZV) antibody and, in follow-up immunologic studies, lymphocyte proliferative response was added. In some cases, blood culture and polymerase chain reaction with Southern hybridization were used for detection of viremia. Results. Among the 27 children in the treatment group, two (7.4%) developed the disease and seroconversion was observed in 17 subjects (63%). Follow-up immunologic studies in 12 of these 17 seroconverted subjects 30 months later showed persistent cellular and/or humoral immunity to VZV. Only one subject, bled 11 days after exposure, had positive VZV DNA and blood culture for VZV. On the other hand 10 of 13 (77%) control subjects developed clinical varicella. Conclusions. Oral ACV administration to healthy susceptible subjects at the beginning of secondary viremia in the late incubation period (9 days after exposure) can effectively prevent or modify clinical varicella.

Original languageEnglish
Pages (from-to)1162-1165
Number of pages4
JournalPediatric Infectious Disease Journal
Volume16
Issue number12
DOIs
Publication statusPublished - Dec 1997
Externally publishedYes

Fingerprint

Human Herpesvirus 3
Acyclovir
Chickenpox
Viremia
Humoral Immunity
Immunoenzyme Techniques
Cellular Immunity
Oral Administration
Healthy Volunteers
Lymphocytes
Polymerase Chain Reaction
Antibodies
DNA
Blood Culture
Therapeutics

Keywords

  • Acyclovir
  • Incubation period
  • Prophylaxis
  • Varicella
  • Varicella-zoster virus

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Oral acyclovir prophylaxis of varicella after intimate contact. / Lin, Tzou Yien; Huang, Yhu Chering; Ning, Hsiao Chen; Hsueh, Chuen.

In: Pediatric Infectious Disease Journal, Vol. 16, No. 12, 12.1997, p. 1162-1165.

Research output: Contribution to journalArticle

Lin, Tzou Yien ; Huang, Yhu Chering ; Ning, Hsiao Chen ; Hsueh, Chuen. / Oral acyclovir prophylaxis of varicella after intimate contact. In: Pediatric Infectious Disease Journal. 1997 ; Vol. 16, No. 12. pp. 1162-1165.
@article{82bc18fa0a3e4e54ab84e46e82c4c53e,
title = "Oral acyclovir prophylaxis of varicella after intimate contact",
abstract = "Objectives. Whether oral acyclovir (ACV) given in late incubation can prevent clinical varicella or not. Materials and methods. Twenty-seven healthy infants and children susceptible to varicella received oral ACV (40 mg/kg daily in four divided doses) for 5 days, starting 9 or 11 days after exposure from the index case in the family (2 in the classroom). The clinical features were compared with 13 control children who did not receive ACV. Enzyme-linked immunoassay was used to detect varicella-zoster virus (VZV) antibody and, in follow-up immunologic studies, lymphocyte proliferative response was added. In some cases, blood culture and polymerase chain reaction with Southern hybridization were used for detection of viremia. Results. Among the 27 children in the treatment group, two (7.4{\%}) developed the disease and seroconversion was observed in 17 subjects (63{\%}). Follow-up immunologic studies in 12 of these 17 seroconverted subjects 30 months later showed persistent cellular and/or humoral immunity to VZV. Only one subject, bled 11 days after exposure, had positive VZV DNA and blood culture for VZV. On the other hand 10 of 13 (77{\%}) control subjects developed clinical varicella. Conclusions. Oral ACV administration to healthy susceptible subjects at the beginning of secondary viremia in the late incubation period (9 days after exposure) can effectively prevent or modify clinical varicella.",
keywords = "Acyclovir, Incubation period, Prophylaxis, Varicella, Varicella-zoster virus",
author = "Lin, {Tzou Yien} and Huang, {Yhu Chering} and Ning, {Hsiao Chen} and Chuen Hsueh",
year = "1997",
month = "12",
doi = "10.1097/00006454-199712000-00012",
language = "English",
volume = "16",
pages = "1162--1165",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Oral acyclovir prophylaxis of varicella after intimate contact

AU - Lin, Tzou Yien

AU - Huang, Yhu Chering

AU - Ning, Hsiao Chen

AU - Hsueh, Chuen

PY - 1997/12

Y1 - 1997/12

N2 - Objectives. Whether oral acyclovir (ACV) given in late incubation can prevent clinical varicella or not. Materials and methods. Twenty-seven healthy infants and children susceptible to varicella received oral ACV (40 mg/kg daily in four divided doses) for 5 days, starting 9 or 11 days after exposure from the index case in the family (2 in the classroom). The clinical features were compared with 13 control children who did not receive ACV. Enzyme-linked immunoassay was used to detect varicella-zoster virus (VZV) antibody and, in follow-up immunologic studies, lymphocyte proliferative response was added. In some cases, blood culture and polymerase chain reaction with Southern hybridization were used for detection of viremia. Results. Among the 27 children in the treatment group, two (7.4%) developed the disease and seroconversion was observed in 17 subjects (63%). Follow-up immunologic studies in 12 of these 17 seroconverted subjects 30 months later showed persistent cellular and/or humoral immunity to VZV. Only one subject, bled 11 days after exposure, had positive VZV DNA and blood culture for VZV. On the other hand 10 of 13 (77%) control subjects developed clinical varicella. Conclusions. Oral ACV administration to healthy susceptible subjects at the beginning of secondary viremia in the late incubation period (9 days after exposure) can effectively prevent or modify clinical varicella.

AB - Objectives. Whether oral acyclovir (ACV) given in late incubation can prevent clinical varicella or not. Materials and methods. Twenty-seven healthy infants and children susceptible to varicella received oral ACV (40 mg/kg daily in four divided doses) for 5 days, starting 9 or 11 days after exposure from the index case in the family (2 in the classroom). The clinical features were compared with 13 control children who did not receive ACV. Enzyme-linked immunoassay was used to detect varicella-zoster virus (VZV) antibody and, in follow-up immunologic studies, lymphocyte proliferative response was added. In some cases, blood culture and polymerase chain reaction with Southern hybridization were used for detection of viremia. Results. Among the 27 children in the treatment group, two (7.4%) developed the disease and seroconversion was observed in 17 subjects (63%). Follow-up immunologic studies in 12 of these 17 seroconverted subjects 30 months later showed persistent cellular and/or humoral immunity to VZV. Only one subject, bled 11 days after exposure, had positive VZV DNA and blood culture for VZV. On the other hand 10 of 13 (77%) control subjects developed clinical varicella. Conclusions. Oral ACV administration to healthy susceptible subjects at the beginning of secondary viremia in the late incubation period (9 days after exposure) can effectively prevent or modify clinical varicella.

KW - Acyclovir

KW - Incubation period

KW - Prophylaxis

KW - Varicella

KW - Varicella-zoster virus

UR - http://www.scopus.com/inward/record.url?scp=0031441456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031441456&partnerID=8YFLogxK

U2 - 10.1097/00006454-199712000-00012

DO - 10.1097/00006454-199712000-00012

M3 - Article

C2 - 9427463

AN - SCOPUS:0031441456

VL - 16

SP - 1162

EP - 1165

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 12

ER -